Eterna Therapeutics Inc.
ERNA
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, aā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.52
Price+2.03%
$0.09
1Y
Price
Market Cap
$1.420m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR+218.6%
3y CAGR+164.0%
5y CAGREarnings
-$11.387m
+19.2%
1y CAGR-6.0%
3y CAGR-1.5%
5y CAGREPS
-$30.70
+45.2%
1y CAGR+21.3%
3y CAGR+28.4%
5y CAGRBook Value
$6.859m
$10.543m
Assets$3.684m
Liabilities$389k
DebtDebt to Assets
3.7%
-
Debt to EBITDAFree Cash Flow
-$7.255m
-2.8%
1y CAGR+24.8%
3y CAGR+19.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company